BeOne Medicines(DE:49BA)
€346.00+0.00 (+3.59%)
DE:49BA
BeOne Medicines stock forecast
€346.00
At close:+0.00 (+3.59%)
BeOne Medicines (49BA) Stock Forecast & Price Target
4 Followers
49BA Analyst Ratings
Strong Buy
12Buy0Hold0Sell
Based on 12 analysts giving stock ratings to BeOne Medicines in the past 3 months
49BA Stock 12 Month Forecast
Average Price Target
EUR 409.56â–²(18.37% Upside)Based on 12 Wall Street analysts offering 12 month price targets for BeOne Medicines in the last 3 months. The average price target is EUR 409.56 with a high forecast of EUR 446.77 and a low forecast of EUR 383.58. The average price target represents a 18.37% change from the last price of EUR 346.00.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 446.77
AverageEUR 409.56
LowEUR 383.58
Highest Price TargetHighestEUR 446.77Average Price TargetEUR 409.56Lowest Price TargetLowestEUR 383.58
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Etzer Darout | Barclays | EUR 370.20→EUR 397.85 | buy | 14.99%Upside | Reiterated | 11/06/26 | ||
| Reni Benjamin | Citizens JMP | EUR 361.28→EUR 413.02 | buy | 19.37%Upside | Reiterated | 11/06/26 | ||
| Yanan Zhu | Wells Fargo | EUR 356.82→EUR 388.04 | buy | 12.15%Upside | Assigned | 11/06/26 | ||
 Unknown AnalystNot Ranked | Goldman Sachs | EUR 393.66→EUR 446.77 | buy | 29.13%Upside | Reiterated | 11/06/26 | ||
| Jill Wu | CMB International Securities | EUR 394.56→EUR 418.03 | buy | 20.82%Upside | Reiterated | 11/06/26 | ||
| Gregory Renza | Truist Financial | EUR 374.66→EUR 399.64 | buy | 15.50%Upside | Reiterated | 11/06/26 | ||
| Sean Laaman | Morgan Stanley | EUR 379.12→EUR 414.80 | buy | 19.89%Upside | Reiterated | 11/06/26 | ||
| Yaron Werber | TD Cowen | EUR 404.99→EUR 425.51 | buy | 22.98%Upside | Reiterated | 11/06/26 | ||
| Michael Schmidt | Guggenheim | EUR 383.58 | buy | 10.86%Upside | Reiterated | 11/05/26 | ||
| Leonid Timashev | RBC Capital | EUR 409.45→EUR 414.80 | buy | 19.89%Upside | Assigned | 11/05/26 | ||
| Yigal Nochomovitz | Citi | EUR 415.70 | buy | 20.14%Upside | Reiterated | 10/19/26 | ||
| Jessica Fye | J.P. Morgan | EUR 379.12→EUR 396.96 | buy | 14.73%Upside | Reiterated | 10/01/26 | ||
| Kalpit Patel | Wolfe Research | EUR 303.30→EUR 330.06 | buy | -4.61%Downside | Assigned | 08/09/26 | ||
| David Li | Bank of America Securities | EUR 360.21→EUR 377.34 | buy | 9.06%Upside | Reiterated | 08/06/26 | ||
| Faisal Khurshid | Jefferies | EUR 297.05→EUR 338.98 | buy | -2.03%Downside | Upgraded | 07/12/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Etzer DaroutBarclays | BuyReiteratedEUR 370.20→EUR 397.85 | 11/06/26 | 14.99%Upside | ||
| Reni BenjaminCitizens JMP | BuyReiteratedEUR 361.28→EUR 413.02 | 11/06/26 | 19.37%Upside | ||
| Yanan ZhuWells Fargo | BuyAssignedEUR 356.82→EUR 388.04 | 11/06/26 | 12.15%Upside | ||
| Unknown AnalystGoldman SachsNot Ranked | BuyReiteratedEUR 393.66→EUR 446.77 | 11/06/26 | 29.13%Upside | ||
| Jill WuCMB International Securities | BuyReiteratedEUR 394.56→EUR 418.03 | 11/06/26 | 20.82%Upside | ||
| Gregory RenzaTruist Financial | BuyReiteratedEUR 374.66→EUR 399.64 | 11/06/26 | 15.50%Upside | ||
| Sean LaamanMorgan Stanley | BuyReiteratedEUR 379.12→EUR 414.80 | 11/06/26 | 19.89%Upside | ||
| Yaron WerberTD Cowen | BuyReiteratedEUR 404.99→EUR 425.51 | 11/06/26 | 22.98%Upside | ||
| Michael SchmidtGuggenheim | BuyReiteratedEUR 383.58 | 11/05/26 | 10.86%Upside | ||
| Leonid TimashevRBC Capital | BuyAssignedEUR 409.45→EUR 414.80 | 11/05/26 | 19.89%Upside | ||
| Yigal NochomovitzCiti | BuyReiteratedEUR 415.70 | 10/19/26 | 20.14%Upside | ||
| Jessica FyeJ.P. Morgan | BuyReiteratedEUR 379.12→EUR 396.96 | 10/01/26 | 14.73%Upside | ||
| Kalpit PatelWolfe Research | BuyAssignedEUR 303.30→EUR 330.06 | 08/09/26 | -4.61%Downside | ||
| David LiBank of America Securities | BuyReiteratedEUR 360.21→EUR 377.34 | 08/06/26 | 9.06%Upside | ||
| Faisal KhurshidJefferies | BuyUpgradedEUR 297.05→EUR 338.98 | 07/12/26 | -2.03%Downside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering BeOne Medicines
3 Months
Success Rate7/9 ratings generated profit
78%
Average Return
+10.78%
Copying David Li's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +10.78% per trade.
1 Year
Success Rate13/13 ratings generated profit
100%
Average Return
+24.28%
Copying Gregory Renza's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +24.28% per trade.
2 Years
Success Rate9/9 ratings generated profit
100%
Average Return
+57.38%
Copying Reni Benjamin's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +57.38% per trade.
49BA Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 0 | 0 | 0 |
| Buy | 25 | 25 | 22 | 23 | 20 |
| Hold | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 32 | 31 | 22 | 23 | 20 |
In the current month, 49BA has received 20 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 49BA average Analyst price target in the past 3 months is 409.56.
49BA Financial Forecast
HighEUR 3.22
ConsensusEUR 2.06
LowEUR 1.11
49BA Earnings Forecast
Next quarter’s earnings estimate for 49BA is EUR 2.06 with a range of EUR 1.11 to EUR 3.22. The previous quarter’s EPS was EUR 2.91. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 1.75B
ConsensusEUR 1.68B
LowEUR 1.6B
49BA Sales Forecast
Next quarter’s sales forecast for 49BA is EUR 1.68B with a range of EUR 1.60B to EUR 1.75B. The previous quarter’s sales results were EUR 1.70B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
49BA Stock Forecast FAQ
What is DE:49BA’s average 12-month price target, according to analysts?
Based on analyst ratings, BeOne Medicines’s 12-month average price target is €409.56.
What is DE:49BA’s upside potential, based on the analysts’ average price target?
BeOne Medicines has 18.37% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BeOne Medicines a Buy, Sell or Hold?
BeOne Medicines has a consensus rating of Strong Buy, which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
What is BeOne Medicines’s share price target?
The average share price target for BeOne Medicines is €409.56. This is based on 12 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €446.77, and the lowest forecast is €383.58. The average share price target represents a 18.37% increase from the current price of €346.
What do analysts say about BeOne Medicines?
BeOne Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Street analysts.
How can I buy shares of BeOne Medicines?
To buy shares of DE:49BA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
